创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

卞正颖, 许卓, 唐铁军, 郭薇. 诱导肿瘤发生免疫原性细胞死亡的疗法研究进展[J]. 药学进展, 2021, 45(2): 119-129.
引用本文: 卞正颖, 许卓, 唐铁军, 郭薇. 诱导肿瘤发生免疫原性细胞死亡的疗法研究进展[J]. 药学进展, 2021, 45(2): 119-129.
BIAN Zhengying, XU Zhuo, TANG Tiejun, GUO Wei. Advances of Research on Therapies for Inducing Tumor Immunogenic Cell Death[J]. Progress in Pharmaceutical Sciences, 2021, 45(2): 119-129.
Citation: BIAN Zhengying, XU Zhuo, TANG Tiejun, GUO Wei. Advances of Research on Therapies for Inducing Tumor Immunogenic Cell Death[J]. Progress in Pharmaceutical Sciences, 2021, 45(2): 119-129.

诱导肿瘤发生免疫原性细胞死亡的疗法研究进展

Advances of Research on Therapies for Inducing Tumor Immunogenic Cell Death

  • 摘要: 激活机体的适应性抗肿瘤免疫应答对于长期的抗肿瘤疗效具有重要意义。放射治疗和某些化疗药物等不仅可以诱导细胞凋亡,还可以诱导肿瘤细胞免疫原性细胞死亡(ICD)。发生ICD的肿瘤细胞释放损伤相关分子模式(DAMPs),招募抗原呈递细胞吞噬加工肿瘤细胞抗原,并进一步激活T细胞适应性免疫应答。因此,将ICD诱导剂应用到肿瘤治疗中,对于改善癌症患者预后、延长患者生存期具有重要意义。综述ICD的分子标记以及ICD诱导剂研究进展,为ICD诱导剂的临床应用提供参考。

     

    Abstract: It is fundamental to activate systemic immune response for long-term anti-tumor efficacy in vivo. Radiotherapy and chemotherapy can not only induce apoptosis, but also immunogenic cell death (ICD) of tumor cells. Once tumor cells undergo ICD, dying cells release damage-related molecular patterns (DAMPs), which then recruit antigen-presenting cells to engulf and process tumor cell antigens, and further activate adaptive immune response. Therefore, the application of ICD inducers in tumor therapy is of great significance for improving the prognosis and prolonging survival of cancer patients. This article reviews the biomarkers of ICD and the research progress of ICD inducers to provide reference for the clinical application of ICD inducers.

     

/

返回文章
返回